View More View Less
  • 1 School of Pharmacy, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
  • | 2 Department of Pharmacy, University of Tirana, Street of Dibres, Tirana, Albania
Restricted access

Abstract

Formulation of poorly water-soluble crystalline drugs into their more soluble amorphous form is a common approach for improving their bioavailability. In this study, the amorphous forms of nicergoline (NIC) and cabergoline (CAB) were obtained by different methods (melting and precipitation under solvent evaporation). The physicochemical characteristics of the samples were determined by HPLC, differential scanning calorimetry (DSC), thermogravimetry, and X-ray powder diffractometry. The physical stability of the amorphous forms was investigated by DSC by considering how the onset temperature and the enthalpy content at the glass transition vary with aging time and temperature. Using the Kohlrausch–Williams–Watts equation on the data obtained from the experiments, the “mean molecular relaxation time constant” (τ) was estimated. This parameter was used to understand the stability of NIC and CAB in their glassy state at different temperatures, and results showed that their stability is adequate to enable the formulation of these drugs into solid dosage forms.

  • 1. Yu, L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;48:2742. .

  • 2. Hancock, BC. Disordered drug delivery: destiny, dynamics and the Deborah number. J Pharm Pharmacol. 2002;54:737746. .

  • 3. Chawla, G, Bansal, AK. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur J Pharm Sci. 2007;32:4557. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4. Leuner, C, Dressman, J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50:4760. .

  • 5. Ambike, AA, Mahadik, KR, Paradkar, A. Stability study of amorphous valdecoxib. Int J Pharm. 2004;282:151162. .

  • 6. Watanabe, T, Wakiyama, N, Usui, F, Ikeda, M, Isobe, T, Senna, M. Stability of amorphous indomethacin compounded with silica. Int J Pharm. 2001;226:8191. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7. Shimpi, SL, Chauhan, B, Mahadik, KR, Paradkar, A. Stabilization and improved in vivo performance of amorphous etoricoxib using gelucire 50/13. Pharm Res. 2005;22:17271734. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8. Gashi, Z, Censi, R, Malaj, L, Gobetto, R, Mozzicafreddo, M, Angeletti, M, Masic, A, Di Martino, P. Differences in the interaction between arylpropionic acid derivatives and poly(vinylpyrrolidone) K30: a multi-methodological approach. J Pharm Sci. 2009;98:42164228. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9. Heitz, C, Descombes, JJ, Miller, RC, Stoclet, JC. α-adrenoceptor antagonistic and calcium antagonistic effects of nicergoline in the rat isolated aorta. Eur J Pharmacol. 1986;123:279285. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10. Brossi, A. The alkaloids. Chemistry and pharmacology, vol 38. San Diego: Academic Press Inc; 1990 142.

  • 11. Venn, RD. Review of clinical studies with ergots in gerontology Goldstein, M, Liberman, A, Calne, DB, Thorner, MO, eds. Ergot compounds and brain function. New York: Raven Press; 1980 363377.

    • Search Google Scholar
    • Export Citation
  • 12. Goo, D, Palosi, E, Szporny, L. Comparison of the effects of vinpocetine, vincamine, and nicergoline on the normal and hypoxia-damaged learning process in spontaneously hypertensive rats. Drug Dev Res. 1988;15:7585. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13. Pastoris, O, Vercesi, L, Allorio, F, Dossena, M. Effect of hypoxia, aging and pharmacological treatment on muscular metabolites and enzyme activities. Il Farmaco Ed Sci. 1988;43:627642.

    • Search Google Scholar
    • Export Citation
  • 14. Triulzi, E, Devizzi, S, Margonato, A. Use of nicergoline in acute myocardial infarction with diastolic hypertension. Il Farmaco Ed Prat. 1981;36:449455.

    • Search Google Scholar
    • Export Citation
  • 15. Hušák, M, Had, J, Kratochvíl, B, Cvak, L, Stuchlík, J, Jegorov, A. X-ray absolute structure of nicergoline (form I). Quantitative analysis of nicergoline phase mixture: FormI/form II. Collect Czechoslov Chem Commun. 1994;59:16241636. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16. Hušák, M, Kratochvil, B, Ondraček, J, Maixner, J, Jerolov, A, Stuchlik, J. The crystal and absolute molecular structure of “low melting” nicergoline (form II). Z Kristallogr. 1994;209:260262. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17. Foresti, E, Sabatino, P, Riva di Sanseverino, L, Fusco, R, Tosi, C, Tonani, R. Structure and molecular orbital study of ergoline derivatives. 1-(6-Methyl-8β-ergolinylmethyl)imidazolidine-2,4-dione (I) and 2-(10-methoxy-1,6-dimethyl-8β-ergolinyl)ethyl 3,5-dimethyl-1H-2-pyrrolecarboxylate toluene hemisolvate (II) and comparison with nicergoline (III). Acta Cryst. 1988;B44:307315.

    • Search Google Scholar
    • Export Citation
  • 18. Malaj, L, Censi, R, Capsoni, D, Pellegrino, L, Bini, M, Ferrari, S, Gobetto, R, Massarotti, V, Di Martino, P. Characterization of nicergoline polymorphs crystallized in several organic solvents. J Pharm Sci. 2011;100:26102622. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19. Colao, A, Di Sarno, A, Pivonello, R, Di Somma, C, Lombardi, G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs. 2002;11:787800. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20. Olanow, CW. The scientific basis for the current treatment of Parkinson’s disease. Ann Rev Med. 2004;55:4160. .

  • 21. Sabatino, P, Riva Di Sanseverino, L, Tonani, R. X-ray crystal structure and conformational analysis of N-(3-dimethylaminopropyl)-N-(ethylaminocarbonyl)-6-(2-propenyl)ergoline-8β-carboxamide (cabergoline): comparison with bromocriptine and lisuride and a hypothesis for its high dopaminergic activity. Il Farmaco. 1995;50:175178.

    • Search Google Scholar
    • Export Citation
  • 22. Bednář, R, Cvak, L, Čejka, J, Kratochvíl, B, Císařová, I, Jegorov, A. Cabergoline, form VII. Acta Cryst. 2004;E60:o1167o1169.

    • Search Google Scholar
    • Export Citation
  • 23. Jegorov, A, Cvak, L, Bednář, R, Čejka, J, Hušák, M, Kratochvíl, B, Císařová, I. Structures of cabergoline anhydrate form II and novel cabergoline solvates. Struct Chem. 2006;17:131137. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24. Hanckock, BC, Zografi, G. Characteristics and significance of the amorphous state. J Pharm Sci. 1997;6:112. .

  • 25. Di Martino, P, Palmieri, GF, Martelli, S. Molecular mobility of the paracetamol amorphous form. Chem Pharm Bull. 2000;48:11051108. .

  • 26. Cao, J, Long, Y, Shanks, RA. Experimental investigation into the heat capacity measurement using an modulated DSC. J Therm Anal Calorim. 1997;50:365373. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27. Venkata Krishnan, R, Nagarajan, K. Evaluation of heat capacity measurements by temperature-modulated differential scanning calorimetry. J Therm Anal Calorim. 2010;102:11351140. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28. Zografi, G. States of water associated with solids. Drug Dev Ind Pharm. 1988;14:19051926. .

  • 29. Ahlneck, C, Zografi, G. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int J Pharm. 1990;62:8795. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30. Andronis, V, Yoshioka, M, Zografi, G. Effect of sorbed water on crystallization of indomethacin from the amorphous state. J Pharm Sci. 1997;86:346351. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31. Schmitt, E, Davis, CW, Long, ST. Moisture-dependent crystallization of amorphous lamotrigine mesylate. J Pharm Sci. 1996;85:12151219. .

  • 32. Tong, P, Zografi, G. Solid-state characteristics of amorphous indomethacin relative to its free acid. Pharm Res. 1999;16:11861192. .

  • 33. Gunawan, L, Johari, GP, Shanker, RM. Structural relaxation of acetaminophen glass. Pharm Res. 2006;23:967979. .

  • 34. Di Martino, P. Crystal growth from pharmaceutical melts Seifer, ED, eds. Bosons, ferromagnetism and crystal growth research. Horizons in world physics. 257 New York: Nova Publisher; 2007 221245.

    • Search Google Scholar
    • Export Citation
  • 35. Van den Mooter, G, Augustijns, P, Kinget, R. Stability prediction of amorphous benzodiazepines by calculation of the mean relaxation time constant using the Williams-Watts decay function. Eur J Pharm Biopharm. 1999;48:4348. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36. Six, K, Verreck, G, Peeters, J, Augustijns, P, Kinget, R, Van den Mooter, G. Characterization of glassy itraconazole: a comparative study of its molecular mobility below Tg with that of structural analogues using MTDSC. Int J Pharm. 2001;213:163173. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37. Vasukumar, K, Bansal, AK. Enthalpy relaxation studies on celecoxib amorphous mixtures. Pharm Res. 2002;19:18731878. .

  • 38. Marsac, PJ, Konno, H, Taylor, LS. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res. 2006;23:23062316. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39. Montserrat, S. Physical aging studies in epoxy resins. I. Kinetics of the enthalpy relaxation process in a fully cured epoxy resin. J Polym Sci B Polym Phys. 1994;32:509522. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40. Fukuoka, E, Makita, M, Yamamura, S. Glassy state of pharmaceuticals. III. Thermal properties and stability of glassy pharmaceuticals and their binary glass systems. Chem Pharm Bull. 1989;37:10471050. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41. Yoshioka, M, Hancock, BC, Zografi, G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci. 1994;83:17001705. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42. Hancock, BC, Shamblin, SL, Zografi, G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res. 1995;12:799806. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43. Bauwens-Crowet, C, Bauwens, JC. Annealing of polycarbonate below the glass transition temperature. Polymer. 1986;27:709713. .

  • 44. Kemmish, DJ, Hay, JN. The effect of physical ageing on the properties of amorphous PEEK. Polymer. 1985;26:905912. .

  • 45. Williams, G, Watts, DC. Non-symmetrical dielectric relaxation behaviour arising from a simple empirical decay function. Trans Faraday Soc. 1970;66:8085. .

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46. Hancock, BC, Christensen, K, Shamblin, SL. Estimating the critical molecular mobility temperature (TK) of amorphous pharmaceuticals. Pharm Res. 1998;15:16491650. .

    • Crossref
    • Search Google Scholar
    • Export Citation